Eisai Fights To Maintain Aricept Patent Rights While Resuming Development On Next Generation Therapy
This article was originally published in PharmAsia News
Executive Summary
TOKYO - The preliminary injunction against generic company Teva Pharmaceuticals for its abbreviated new drug application pending at U.S. FDA of Japanese company Eisai's Alzheimer's drug Aricept (donepezil) will have very minimal impact on the generic drug industry as a whole, a Japanese patent lawyer told PharmAsia News